DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
VX-661 is an investigational drug.
There have been 34 clinical trials for VX-661. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2015.
The most common disease conditions in clinical trials are Cystic Fibrosis, Fibrosis, and [disabled in preview]. The leading clinical trial sponsors are Vertex Pharmaceuticals Incorporated and [disabled in preview].
There are sixty-five US patents protecting this investigational drug and six hundred and ninety-one international patents.
Recent Clinical Trials for VX-661
|A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes||Vertex Pharmaceuticals Incorporated||Phase 3|
|A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy||Vertex Pharmaceuticals Incorporated||Phase 3|
|Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older||Vertex Pharmaceuticals Incorporated||Phase 3|
Top disease conditions for VX-661
Top clinical trial sponsors for VX-661
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|VX-661||Start Trial||Compounds, compositions, and methods for increasing CFTR activity||Proteostasis Therapeutics, Inc. (Boston, MA)||Start Trial|
|VX-661||Start Trial||Modulators of ATP-binding cassette transporters||Vertex Pharmaceuticals Incorporated (Boston, MA)||Start Trial|
|VX-661||Start Trial||Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6- -fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof||Vertex Pharmaceuticals Incorporated (Boston, MA)||Start Trial|
|VX-661||Start Trial||Process of producing cycloalkylcarboxamido-indole compounds||Vertex Pharmaceuticals Incorporated (Boston, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|VX-661||European Patent Office||3116870||2034-03-13||Start Trial|
|VX-661||World Intellectual Property Organization (WIPO)||2015138934||2034-03-13||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|